ANDA 209734, held by Strides Pharma. Acetazolamide.
As of Nov 13, 2026, ANDA 209734 (Acetazolamide), held by Strides Pharma, was first approved by FDA on Nov 20, 2017, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Nov 20, 2017 | Original application | Approved |
| Acetazolamide125MG · tablet;oral | Acetazolamide | Rx |
| Acetazolamide250MG · tablet;oral | Acetazolamide | Rx |
| Jan 8, 2026 | Supplement 19Labeling · Standard review | Approved | None posted |
| Sep 16, 2025 | Supplement 16Labeling · Standard review | Approved | None posted |
| Jul 26, 2022 | Supplement 7Labeling · Standard review | Approved | None posted |
| Nov 20, 2017 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
